Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma

Wenqing Qi, Laurence S. Cooke, Xiaobing Liu, Lisa Rimsza, Denise J. Roe, Ann Manziolli Daniel O. Persky, Thomas P. Miller, Daruka Mahadevan

Research output: Contribution to journalArticlepeer-review

70 Scopus citations


Auroras (A and B) are oncogenic serine/threonine kinases that play key roles in the mitotic phase of the eukaryotic cell cycle. Analysis of the leukemia lymphoma molecular profiling project (LLMPP) database indicates Aurora over-expression correlates with poor prognosis. A tissue microarray (TMA) composed of 20 paired mantle cell lymphoma (MCL) patients demonstrated >75% of patients had high levels Aurora expression. Aurora A and B were also found elevated in 13 aggressive B-NHL cell lines. MLN8237, an Aurora inhibitor induced G2/M arrest with polyploidy and abrogated Aurora A and histone-H3 phosphorylation. MLN8237 inhibited aggressive B-NHL cell proliferation at an IC50 of 10-50 nM and induced apoptosis in a dose- and time-dependent manner. Low dose combinations of MLN8237 + docetaxel enhanced apoptosis by ∼3-4-fold in cell culture compared to single agents respectively. A mouse xenograft model of MCL demonstrated that MLN8237 (10 or 30 mg/kg) or docetaxel (10 mg/kg) alone had modest anti-tumor activity. However, MLN8237 plus docetaxel demonstrated a statistically significant tumor growth inhibition and enhanced survival compared to single agent therapy. Together, our results suggest that MLN8237 plus docetaxel may represent a novel therapeutic strategy that could be evaluated in early phase trials in relapsed/refractory aggressive B-cell NHL.

Original languageEnglish (US)
Pages (from-to)881-890
Number of pages10
JournalBiochemical Pharmacology
Issue number7
StatePublished - Apr 1 2011


  • Aurora A and B
  • Aurora Inhibitor
  • Docetaxel
  • MLN8237
  • Mantle cell lymphoma (MCL)
  • Non-Hodgkin lymphoma (NHL)

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology


Dive into the research topics of 'Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma'. Together they form a unique fingerprint.

Cite this